Cognition Therapeutics, Inc. CGTX 深 沪
已收盘 08-01 16:00:00 美东时间
0.6674
+0.082
+13.93%
华盛通- 最 高0.6996
- 今 开0.5555
- 成交量 408.99万股
- 最 低 0.5555
- 昨 收 0.5858
- 总市值 4137.41万
- 52周最高 1.29
- 市盈率 静 --
- 换手率 6.60%
- 52周最低 0.2223
- 委 比 -40.95%
- 总股本 6199.30万
- 历史最高 13.80
- 量 比 0.89
- 振 幅 24.60%
- 历史最低 0.2223
- 每 手 1
- 风险率 0.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cognition Therapeutics Presents Results From Phase 2 COG1201 SHIMMER Study Of Zervimesine In Dementia With Lewy Bodies At AAIC 2025
- Zervimesine's impact on debilitating DLB behavioral symptoms highlighted in podium presentation -- Plasma p-tau217 levels can identify Alzheimer's patients most likely to benefit from zervimesine treatment -- Plasma
07-29 19:38
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease
Cognition Therapeutics presented Phase 2 results for zervimesine in DLB and Alzheimer’s disease. In DLB, zervimesine improved neuropsychiatric symptoms like hallucinations and anxiety by 86% vs. placebo. In Alzheimer’s, plasma p-tau217 levels identified patients more likely to benefit, with zervimesine arresting cognitive decline by 129% and 91% in mild and moderate cases. Biomarkers showed reductions in neuroinflammation and neurodegeneration pr...
07-29 11:30
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease
Cognition Therapeutics Inc. announced results from its Phase 2 SEQUEL study of zervimesine (CT1812), showing improvements in EEG parameters and neuroprotective effects in mild-to-moderate Alzheimer's disease patients. The study revealed reduced theta waves and increased functional connectivity, suggesting zervimesine may normalize synaptic function. Proteomics analysis linked the drug to processes involving vesicle formation and endosomal traffic...
07-21 11:30
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC
Cognition Therapeutics announced positive results from the Phase 2 SHIMMER study of zervimesine in patients with dementia with Lewy bodies (DLB), showing significant improvements in behavioral, cognitive, and motor symptoms. The study, supported by an NIH grant, demonstrated that zervimesine-treated participants performed 86% better in behavioral outcomes and 91% better in cognitive fluctuations compared to placebo. Additionally, in the Phase 2 S...
07-16 11:30
Cognition Therapeutics shares are trading higher after the company completed an End-of-Phase 2 meeting with the FDA for Zervimesine in Alzheimer's disease.
Cognition Therapeutics shares are trading higher after the company completed an...
07-10 19:33
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease
Cognition Therapeutics Inc. (NASDAQ: CGTX) held an end-of-Phase 2 meeting with the FDA to review results of the Phase 2 SHINE Study for zervimesine (CT1812) and discuss Phase 3 plans for its potential approval as an Alzheimer’s disease treatment. Lisa Ricciardi, CEO, expressed confidence in the path forward after the meeting. Zervimesine, an oral drug targeting neurodegenerative diseases, aims to disrupt toxic effects of Aβ and α-synuclein protei...
07-10 11:30
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 171.6% to $27....
07-07 20:07
Sonnet BioTherapeutics Drops 5% Intraday, Rebounds 14% After Hours Amid Delisting Concerns
Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) fell 5.54% on Thursday to close at $3.92, before rebounding 14.29% in after-hours trading to $4.48, amid concerns of a potential NASDAQ delisting.
07-04 11:42
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target
Cognition Therapeutics, Inc. announced that its Phase 2 START Study for treating early Alzheimer’s disease has surpassed 50% enrollment. The study, conducted with the Alzheimer’s Clinical Trials Consortium (ACTC) and supported by an $81 million grant from the National Institute of Aging (NIA), aims to enroll up to 540 participants to evaluate the safety and efficacy of zervimesine, an oral investigational drug. Earlier Phase 2 results showed zerv...
07-01 11:30
美股大行评级 | 潜在涨幅61.27%！Loop Capital上调英伟达目标价至250美元，维持"买入"评级
今日重点评级关注：Benchmark：维持特斯拉(TSLA)"买入"评级，目标价从350美元升至475美元>>
06-27 08:37
